NYSE:BVS Bioventus (BVS) Stock Forecast, Price & News $2.94 -0.01 (-0.34%) (As of 10:16 AM ET) Add Compare Share Share Today's Range$2.89▼$2.9950-Day Range$2.91▼$4.9452-Week Range$0.80▼$8.29Volume5,899 shsAverage Volume824,487 shsMarket Capitalization$231.03 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Bioventus MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside92.7% Upside$5.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$854,928 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to $0.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector254th out of 961 stocksSurgical & Medical Instruments Industry29th out of 98 stocks 3.1 Analyst's Opinion Consensus RatingBioventus has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, Bioventus has a forecasted upside of 92.7% from its current price of $2.94.Amount of Analyst CoverageBioventus has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BVS. Previous Next 0.0 Dividend Strength Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BVS. Previous Next 2.7 News and Social Media Coverage News SentimentBioventus has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bioventus this week, compared to 1 article on an average week.Search Interest5 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have bought 76,575.16% more of their company's stock than they have sold. Specifically, they have bought $854,928.00 in company stock and sold $1,115.00 in company stock.Percentage Held by Insiders29.10% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.65% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bioventus are expected to grow in the coming year, from ($0.83) to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bioventus (NYSE:BVS) StockBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More BVS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVS Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comBioventus to Present at the Cantor Global Healthcare ConferenceSeptember 6, 2023 | finance.yahoo.comBioventus to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 26, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 23, 2023 | benzinga.comBioventus And 3 Other Stocks Under $5 Insiders Are BuyingAugust 16, 2023 | finance.yahoo.comJuniper Investment Company, LLC Increases Stake in Bioventus IncAugust 10, 2023 | finance.yahoo.comBioventus works to trim debt under interim CEOAugust 8, 2023 | finanznachrichten.deBioventus, Inc.: Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial GuidanceAugust 8, 2023 | benzinga.com2BVS : Bioventus Earnings PreviewSeptember 26, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 8, 2023 | finance.yahoo.comBioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial GuidanceAugust 2, 2023 | msn.comBioventus Inc - (BVS) Price Target Increased by 40.00% to 3.57August 1, 2023 | finance.yahoo.comBioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023June 4, 2023 | ca.finance.yahoo.comBioventus Inc. (BVS) Stock Price, News, Quote & History - Yahoo FinanceMay 23, 2023 | finance.yahoo.comBioventus Completes Divestiture of its Wound BusinessMay 18, 2023 | finance.yahoo.comBioventus Inc. (NASDAQ:BVS) Q1 2023 Earnings Call TranscriptMay 17, 2023 | finanznachrichten.deBioventus, Inc.: Bioventus Reports First Quarter Financial ResultsMay 16, 2023 | msn.comRecap: Bioventus Q1 EarningsMay 16, 2023 | finance.yahoo.comBioventus Reports First Quarter Financial ResultsMay 15, 2023 | finance.yahoo.comBioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023May 15, 2023 | benzinga.com7BVS : Earnings Preview: BioventusMay 12, 2023 | bizjournals.comBioventus sells assets to LifeNet as Durham company looks to slash debtMay 11, 2023 | bizjournals.comBioventus sells assets as company looks to slash debtMay 11, 2023 | finance.yahoo.comBioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023May 10, 2023 | marketwatch.comBioventus to Sell Its Wound Business to LifeNet HealthMay 10, 2023 | finance.yahoo.comBioventus Announces Divestiture of its Wound BusinessMay 3, 2023 | finance.yahoo.comBioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023April 8, 2023 | finance.yahoo.comWhile institutions invested in Bioventus Inc. (NASDAQ:BVS) benefited from last week's 22% gain, private equity firms stood to gain the mostSee More Headlines Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:BVS CUSIPN/A CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,120Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.67 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+92.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-158,700,000.00 Net Margins-55.42% Pretax Margin-67.05% Return on Equity1.24% Return on Assets0.33% Debt Debt-to-Equity Ratio1.61 Current Ratio1.46 Quick Ratio0.92 Sales & Book Value Annual Sales$510.62 million Price / Sales0.45 Cash Flow$1.67 per share Price / Cash Flow1.77 Book Value$4.37 per share Price / Book0.68Miscellaneous Outstanding Shares78,580,000Free Float55,713,000Market Cap$231.81 million OptionableNot Optionable Beta0.34 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Mark L. Singleton (Age 53)Sr. VP & CFO Comp: $444.12kMr. Anthony P. Bihl III (Age 67)CEO & Director Mr. David CrawfordVP of Investor Relations & TreasurerMr. Anthony D'Adamio (Age 62)Sr. VP, Gen. Counsel & Corp. Sec. Ms. Katrina J. Church J.D. (Age 61)Chief Compliance Officer Ms. Helen LeupoldSr. VP & Chief HR OfficerMr. Larry ChenManaging Director of China & Asia PacificMore ExecutivesKey CompetitorsPulse BiosciencesNASDAQ:PLSELyra TherapeuticsNASDAQ:LYRAQuipt Home MedicalNASDAQ:QIPTAlpha Tau MedicalNASDAQ:DRTSAnika TherapeuticsNASDAQ:ANIKView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 44,022 shares on 8/23/2023Ownership: 0.078%Osaic Holdings Inc.Bought 77,000 shares on 8/21/2023Ownership: 0.098%Anthony P Bihl IIIBought 13,290 shares on 8/18/2023Total: $55,020.60 ($4.14/share)Y Intercept Hong Kong LtdBought 3,688 shares on 8/15/2023Ownership: 0.045%Goldman Sachs Group Inc.Bought 3,861 shares on 8/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions BVS Stock - Frequently Asked Questions Should I buy or sell Bioventus stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVS, but not buy additional shares or sell existing shares. View BVS analyst ratings or view top-rated stocks. What is Bioventus' stock price forecast for 2023? 4 Wall Street research analysts have issued 1-year target prices for Bioventus' shares. Their BVS share price forecasts range from $5.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price. View analysts price targets for BVS or view top-rated stocks among Wall Street analysts. How have BVS shares performed in 2023? Bioventus' stock was trading at $2.61 at the start of the year. Since then, BVS stock has increased by 13.0% and is now trading at $2.95. View the best growth stocks for 2023 here. When is Bioventus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023. View our BVS earnings forecast. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) issued its quarterly earnings results on Tuesday, August, 8th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.11. The business had revenue of $137.07 million for the quarter, compared to the consensus estimate of $128.90 million. Bioventus had a negative net margin of 55.42% and a positive trailing twelve-month return on equity of 1.24%. What guidance has Bioventus issued on next quarter's earnings? Bioventus updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of -$0.24--$0.20 for the period, compared to the consensus estimate of -$0.22. The company issued revenue guidance of $490.00 million-$505.00 million, compared to the consensus revenue estimate of $493.14 million. When did Bioventus IPO? (BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO. What is Bioventus' stock symbol? Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS." Who are Bioventus' major shareholders? Bioventus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Juniper Investment Company LLC (8.51%), Kent Lake Capital LLC (1.15%), BlackRock Inc. (0.60%), Western Standard LLC (0.51%), Geode Capital Management LLC (0.44%) and Stephens Inc. AR (0.35%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bioventus' stock price today? One share of BVS stock can currently be purchased for approximately $2.95. How much money does Bioventus make? Bioventus (NYSE:BVS) has a market capitalization of $231.81 million and generates $510.62 million in revenue each year. The company earns $-158,700,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis. How many employees does Bioventus have? The company employs 1,120 workers across the globe. How can I contact Bioventus? Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The official website for the company is www.bioventus.com. The company can be reached via phone at 919-474-6700 or via email at investor.relations@bioventus.com. This page (NYSE:BVS) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.